1
|
Zeng Z, Shen H, Gao W, Guo Q, Chen M, Yan X, Liu H, Ji Y. A novel biocompatible Eu-based coordination polymers of cytarabine anticancer drug: Preparation, luminescence properties and in vitro anticancer activity studies. Front Chem 2022; 10:1043810. [DOI: 10.3389/fchem.2022.1043810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 10/21/2022] [Indexed: 11/13/2022] Open
Abstract
In this study, we use cytarabine anticancer drug to synthesize a new rare earth complex with Europium ion. The study work is an attempt to investigate luminescence and biological properties of the Eu-based coordination polymers of cytarabine (Eu-CP-Ara) anticancer drug which have been prepared by us. Eu-CP-Ara has luminescence properties with emission centering at about 619 nm excited with 394 nm. We study cytarabine and Eu-CP-Ara in vitro cytotoxicity. Cytotoxicity of Eu-CP-Ara against lung cancer cells (A549) could even be comparable to the inhibitory effect of cytarabine ligands, showing the advantage of antitumor activity. In addition, Eu-CP-Ara showed lower cytotoxicity to normal liver cells (L02). At the same, from the CLSM images, Eu-CP-Ara has successfully entered the A549 cell. Hence, Eu-CP-Ara can be used as a potential anticancer drug. Eu-CP-Ara may be an effective strategy for the tracking cytarabine against tumours and might impart better accurate treatment effect and therapeutic efficiency.
Collapse
|
2
|
Ji Y, Luo K, Zhang JM, Ni P, Xiong W, Luo X, Xu G, Liu H, Zeng Z. Obese rats intervened with Rhizoma coptidis revealed differential gene expression and microbiota by serum metabolomics. BMC Complement Med Ther 2021; 21:208. [PMID: 34380455 PMCID: PMC8359625 DOI: 10.1186/s12906-021-03382-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 07/22/2021] [Indexed: 12/04/2022] Open
Abstract
Background Integrating systems biology is an approach for investigating metabolic diseases in humans. However, few studies use this approach to investigate the mechanism by which Rhizoma coptidis (RC) reduces the effect of lipids and glucose on high-fat induced obesity in rats. Methods Twenty-four specific pathogen-free (SPF) male Sprague–Dawley rats (80 ± 10 g) were used in this study. Serum metabolomics were detected by ultra-high-performance liquid chromatography coupled with quadrupole-time-of-flight tandem mass spectrometry. Liver tissue and cecum feces were used for RNA-Seq technology and 16S rRNA gene sequencing, respectively. Results We identified nine potential biomarkers, which are differential metabolites in the Control, Model and RC groups, including linoleic acid, eicosapentaenoic acid, arachidonic acid, stearic acid, and L-Alloisoleucine (p < 0.01). The liver tissue gene expression profile indicated the circadian rhythm pathway was significantly affected by RC (Q ≤ 0.05). A total of 149 and 39 operational taxonomic units (OTUs), which were highly associated with biochemical indicators and potential biomarkers in the cecum samples (FDR ≤ 0.05), respectively, were identified. Conclusion This work provides information to better understand the mechanism of the effect of RC intervention on hyperlipidemia and hypoglycemic effects in obese rats. The present study demonstrates that integrating systems biology may be a powerful tool to reveal the complexity of metabolic diseases in rats intervened by traditional Chinese medicine. Supplementary Information The online version contains supplementary material available at 10.1186/s12906-021-03382-3.
Collapse
Affiliation(s)
- Yanhua Ji
- Jiangxi Province Key Laboratory of TCM Etiopathogenisis, Research Center for Differention and Development of TCM Basic Theory, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China.,Laboratory Animal Science and Technology Center, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Kexin Luo
- Jiangxi Province Key Laboratory of TCM Etiopathogenisis, Research Center for Differention and Development of TCM Basic Theory, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Jiri Mutu Zhang
- Jiangxi Province Key Laboratory of TCM Etiopathogenisis, Research Center for Differention and Development of TCM Basic Theory, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Peng Ni
- Jiangxi Province Key Laboratory of TCM Etiopathogenisis, Research Center for Differention and Development of TCM Basic Theory, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Wangping Xiong
- School of Computer, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Xiaoquan Luo
- Laboratory Animal Science and Technology Center, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Guoliang Xu
- Jiangxi Province Key Laboratory of TCM Etiopathogenisis, Research Center for Differention and Development of TCM Basic Theory, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China.,Jiangxi Key Lab of Pharmacology of TCM, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Hongning Liu
- Jiangxi Province Key Laboratory of TCM Etiopathogenisis, Research Center for Differention and Development of TCM Basic Theory, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China
| | - Zhijun Zeng
- Jiangxi Province Key Laboratory of TCM Etiopathogenisis, Research Center for Differention and Development of TCM Basic Theory, University of Jiangxi TCM, Nanchang, Jiangxi, 330006, P. R. China.
| |
Collapse
|